CMR Surgical announced that over 30,000 surgical cases worldwide have been completed using the Versius system, making it the second most-used soft-tissue surgical robot.
The Versius Surgical System by CMR Surgical assists in minimally invasive procedures and received FDA clearance in October 2024.
It mimics the human arm and allows precise control over endoscopic instruments, offering flexibility for various surgical tasks.
CMR Surgical introduced vLimeLite, a fluorescence imaging system, and the Ultrasonic Dissector for enhanced surgical capabilities.
Versius benefits include stress reduction for surgeons, 3D HD vision, and data capture for continuous learning and improvement.
More than 70% of hospitals using Versius have applied it in two or more specialties, covering urology, general surgery, gynecology, and thoracic surgery.
CMR Surgical is conducting clinical trials for pediatric surgery and transoral robotic surgery, aiming to expand the benefits of robotic-assisted surgery.
Leading international journals have published clinical evidence on the efficacy of Versius, with FDA marketing authorization for cholecystectomy.
CMR Surgical focuses on expanding Versius benefits to more hospitals globally through new product enhancements and market entries.
With Versius Plus offerings and clinical trials, CMR Surgical aims to bring minimal access surgery advantages to a wider patient population.